Pharma and patient organizations came together this year in celebration of the 10th annual HAE Awareness Day — set…
Articles by Patricia Inácio, PhD
Haegarda is now available to adolescent and adult hereditary angioedema (HAE) patients across Canada for the prevention of HAE…
Japanese researchers have identified a new mutation in the SERPING1 gene linked to hereditary angioedema (HAE) in a 27-year-old…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…
BioCryst Pharmaceuticals is seeking the approval of Orladeyo (berotralstat) in the United Kingdom as a preventive treatment for…
Subcutaneous (under-the-skin) administration of human plasma-derived C1 inhibitor is an effective and safe option for managing hereditary angioedema during…
PHA121, an investigational oral therapy for hereditary angioedema attacks, was well tolerated across multiple doses in…
Just a couple of weeks after its U.S. approval, Orladeyo (berotralstat) is now available for direct shipment to hereditary…
Takeda’s Takhzyro (lanadelumab) has been approved in China for the routine prevention of hereditary angioedema (HAE) attacks in…